Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 158)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxorubicin |
Approved, Investigational |
Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
2 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
3 |
|
Pembrolizumab |
Approved |
Phase 3 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
4 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
5 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
6 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
7 |
|
Metformin |
Approved |
Phase 2, Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
8 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
9 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
10 |
|
Liposomal doxorubicin |
|
Phase 3 |
|
|
|
11 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
12 |
|
Antineoplastic Agents, Immunological |
|
Phase 3 |
|
|
|
13 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
14 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
15 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
16 |
|
Hypoglycemic Agents |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Fulvestrant |
Approved, Investigational |
Phase 2 |
|
129453-61-8 |
17756771 104741 |
Synonyms:
(1S,9R,11S,14S,15S)-15-Methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulphinyl)nonyl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-5,14-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
Faslodex
Faslodex®|ICI 182,780|ICI 182780|ICI182780|ZD-9238
|
FULVESTRANT
ICI 182,780
ICI-182780
SID29215034
ZD-9238
|
|
18 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
19 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
20 |
|
Medroxyprogesterone acetate |
Approved, Investigational |
Phase 2 |
|
520-85-4, 71-58-9 |
6279 10631 |
Synonyms:
(6ALPHA)-17-(ACETYLOXY)-6-METHYLPREG-4-ENE-3,20-DIONE
(6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha methylprogesterone
17 alpha-Hydroxy-6 alpha-methylprogesterone
17-ACETOXY-6ALPHA-METHYLPROGESTERONE
17-ACETOXY-6Α-METHYLPROGESTERONE
17a-Hydroxy-6a-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone
17ALPHA-HYDROXY-6ALPHA-METHYLPROGESTERONE ACETATE
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17-Hydroxy-6a-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6α-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6α-methylprogesterone
17Α-hydroxy-6α-methylprogesterone
17Α-HYDROXY-6Α-METHYLPROGESTERONE ACETATE
6ALPHA-METHYL-17-ACETOXY PROGESTERONE
6-ALPHA-METHYL-17-ALPHA-ACETOXYPROGESTERONE
6alpha-Methyl-17alpha-hydroxyprogesterone
6ALPHA-METHYL-17ALPHA-HYDROXYPROGESTERONE ACETATE
6-ALPHA-METHYL-17-ALPHA-HYDROXYPROGESTERONE ACETATE
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6ALPHA-METHYL-4-PREGNENE-3,20-DION-17ALPHA-OL ACETATE
6a-Methyl-17a-hydroxyprogesterone
6a-Methyl-4-pregnen-17a-ol-3,20-dione
6Α-METHYL-17-ACETOXY PROGESTERONE
6Α-methyl-17α-hydroxyprogesterone
6Α-METHYL-17Α-HYDROXYPROGESTERONE ACETATE
6Α-methyl-4-pregnen-17α-ol-3,20-dione
6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
ADGYN MEDRO
AMEN
Aragest
Aragest 5
Asconale
CBP-1011
CLIMANOR
Clinofem
Clinovir
Colirest
CURRETAB
CYCRIN
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
DEPO-PROGEVERA
Depo-Promone
DEPO-PROVERA
DEPO-PROVERA ONCOLOGY
DEPO-SUBQ PROVERA 104
Depot-Medroxyprogesterone acetate
DMPA
FARLUTAL
FARLUTAL 100
FARLUTAL 200
FARLUTAL 250
FARLUTAL 500
Farlutal inyectable
|
Farlutin
Gestapuran
G-Farlutal
Hematrol
Hydroxymethylprogesterone
hydroxymethylprogesterone|MPA
Hysron
Indivina
LUNELLE
Lutopolar
Lutoral
MAP
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
MEDROXIPROGESTERONE ACETATE
Medroxiprogesteronum
MEDROXYACETATE PROGESTERONE
Medroxyprogesteron
Medroxyprogesteron acetate
MEDROXYPROGESTERONE
MEDROXYPROGESTERONE 17-ACETATE
MEDROXYPROGESTERONE ACETATE
Medroxyprogesterone strakan brand
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
METHYLACETOXYPROGESTERONE
Methylhydroxyprogesterone
METIGESTRONA
MPA
MPA Gyn 5
Nadigest
Nidaxin
Novo-Medrone
NSC-21171
NSC-26386
Oragest
Perlutex
Perlutex Leo
PREMPRO
Prodasone
Progestalfa
Progevera
PROVERA
Proverone
Ralovera
Repromap
Repromix
SAYANA PRESS
Sirprogen
Sodelut G
Strakan brand OF medroxyprogesterone
TV-46046
Veramix
|
|
21 |
|
Bupropion |
Approved |
Phase 2 |
|
31677-93-7, 34841-39-9, 34911-55-2 |
444 |
Synonyms:
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
Amfebutamona
Amfebutamone
AMFEBUTAMONE HCL
amfebutamone|BW-323|Wellbutrin®|Zyban®
Amfebutamonum
BUPROPION
BUPROPION HCL
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion, (+-)-isomer
BW-323
Esteve brand OF bupropion hydrochloride
FORFIVO XL
glaxo Wellcome brand 1 OF bupropion hydrochloride
|
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
NSC-315851
Quomen
Wellbatrin
Wellbutrin
WELLBUTRIN 100
WELLBUTRIN 75
WELLBUTRIN SR
WELLBUTRIN XL
Zyban
Zyban (anti-smoking)
Zyban (bupropion)
Zyntabac
|
|
22 |
|
Dopamine |
Approved |
Phase 2 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
23 |
|
Trastuzumab |
Approved, Investigational |
Phase 2 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
24 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
25 |
|
Letrozole |
Approved, Investigational |
Phase 2 |
|
112809-51-5 |
3902 |
Synonyms:
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
CGS-20267
FEM345
Femara
Fémara
|
Femara®
Letrozol
LETROZOLE
Novartis brand OF letrozole
|
|
26 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
27 |
|
Palbociclib |
Approved, Investigational |
Phase 2 |
|
571190-30-2 |
5330286 |
Synonyms:
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-D)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
IBRANCE
Ibrance®|PD-0332991|PD0332991
PALBOCICLIB
|
PD 0332991
PD 332991
PD0332991
PD-0332991
UNII-g9Zf61le7g
|
|
28 |
|
Mebendazole |
Approved, Vet_approved |
Phase 2 |
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
Abello farmacia brand OF mebendazole
Anti worm
Anti-worm
Ardeypharm brand OF mebendazole
Bantenol
Banworm
Boots brand OF mebendazole
Boots threadworm treatment
Degort's brand OF mebendazole
Diba brand OF mebendazole
Elfar brand OF mebendazole
EMVERM
Esteve brand OF mebendazole
Healthypharm brand OF mebendazole
Janssen brand OF mebendazole
Leidapharm brand OF mebendazole
Lomper
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazole
|
Mébendazole
MEBENDAZOLE POLYMORPH C
Mebendazolum
Mebenvet
Norgine brand OF mebendazole
NSC-184849
OVEX
Pfizer brand OF mebendazole
Pripsen mebendazole
R-17635
Sqworm
SSL Brand OF mebendazole
Streger brand OF mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Tedec meiji brand OF mebendazole
Telmin
TELMINTIC
Vermicol
Vermidil
Vermin
Vermox
Wormkuur
|
|
29 |
|
Piperazine |
Approved, Vet_approved |
Phase 2 |
|
110-85-0 |
4837 |
Synonyms:
1,4 Diazacyclohexane
1,4 Piperazine
1,4-Diazacyclohexane
1,4-Piperazine
Diethylenediamine
Diethyleneimine
Fluphenazine dihydrochloride
Hexahydropyrazine
Piperazidine
Piperazin
Piperazina
Piperazine
Piperazine diacetate
Piperazine dihydrochloride
Piperazine hexahydrate
|
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine phosphate anhydrous
Piperazine salt
Piperazine sulfate
Piperazine tartrate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazinium oleate
Pripsen
Vermizine
|
|
30 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
31 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 2 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
32 |
|
Afatinib |
Approved |
Phase 2 |
|
439081-18-2, 850140-72-6 |
53445376 10184653 |
Synonyms:
AFATINIB
AFATINIBUM
BIBW 2992
BIBW2992
BIBW-2992
|
BIBW2992|Gilotrif®
GILOTRIF
GIOTRIF
Tomtovok
Tovok
|
|
33 |
|
Adenosine |
Approved, Investigational |
Phase 2 |
|
58-61-7 |
60961 |
Synonyms:
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-METHYLOL-TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4S,5R)-2-(6-AMINO-9H-PURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-ribofuranose
6-Amino-9-b-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9-β-D-ribofuranosyl-9H-purine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-Β-D-ribofuranosidoadenine
9-Β-D-ribofuranosyl-9H-purin-6-amine
ADENIN RIBOSIDE
Adenine deoxyribonucleoside
|
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenocard
Adenocard®|Adenoscan®
Adenocor
ADENOGESIC
Adenoscan
Adenosin
ADENOSINA
ADENOSINE
ADÉNOSINE
ADENOSINUM
Adenyldeoxyriboside
Ade-rib
Ado
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
Boniton
Deoxyadenosine
Desoxyadenosine
Myocol
NSC-7652
Nucleocardyl
Sandesin
SR-96225
Β-D-adenosine
|
|
34 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
35 |
|
Pertuzumab |
Approved |
Phase 2 |
|
380610-27-5 |
|
Synonyms:
2C4 ANTIBODY
2C4|Omnitarg® (obsolete trade name)|Perjeta®
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MONOCLONAL ANTIBODY 2C4
|
OMNITARG
OMNITARG PERJETA
PERJETA
PERTUZUMAB
RG-1273
RHUMAB-2C4
|
|
36 |
|
Dabrafenib |
Approved, Investigational |
Phase 2 |
|
1195765-45-7 |
44462760 |
Synonyms:
DABRAFENIB
DRB436
GSK2118436
GSK-2118436
|
GSK2118436|GSK2118436A|Tafinlar®
GSK2118436a
GSK-2118436A
TAFINLAR
|
|
37 |
|
Osimertinib |
Approved |
Phase 2 |
|
1421373-65-0 |
71496458 |
Synonyms:
AZD 9291
AZD 9291|AZD-9291|AZD9291|mereletinib (obsolete INN)|Tagrisso®
AZD9291
AZD-9291
AZD-9291 FREE BASE
Mereletinib
|
MERELETINIB (OBSOLETE INN)
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
OSIMERTINIB
Osimertinibum
Tagrisso
|
|
38 |
|
Crizotinib |
Approved, Investigational |
Phase 2 |
|
877399-52-5 |
11626560 |
Synonyms:
(<i>R</i>)-crizotinib|PF 2341066|PF-02341066|PF-2341066|PF2341066|Xalkori®
(R)-CRIZOTINIB
CRIZOTINIB
Crizotinibum
PF 2341066
|
PF-02341066
PF2341066
PF-2341066
XALKORI
|
|
39 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
40 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
41 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
42 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
43 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
44 |
|
Levonorgestrel |
Approved, Investigational |
Phase 2 |
|
797-63-7 |
13109 |
Synonyms:
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one
(+-)-Norgestrel
(8R,9S,10R,13S,14S,17R)-13-ETHYL-17-ETHYNYL-17-HYDROXY- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- TETRADECAHYDROCYCLOPENTA[A] PHENANTHREN-3-ONE
13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13-b-Ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one
13-Ethyl-17-a-ethynyl-17-b-hydroxy-4-gonen-3-one
13-Ethyl-17-a-ethynylgon-4-en-17-b-ol-3-one
13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
13-Ethyl-17-α-ethynyl-17-β-hydroxy-4-gonen-3-one
13-Ethyl-17-α-ethynylgon-4-en-17-β-ol-3-one
13-Β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one
17-a-Ethinyl-13-b-ethyl-17-b-hydroxy-4-estren-3-one
17a-Ethynyl-13b-ethyl-3-oxo-4-estren-17b-ol
17-a-Ethynyl-13-ethyl-19-nortestosterone
17a-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17a-Ethynyl-18-homo-19-nortestosterone
17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
17-alpha-Ethynyl-13-ethyl-19-nortestosterone
17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17alpha-Ethynyl-18-homo-19-nortestosterone
17-Ethynyl-18-methyl-19-nortestosterone
17-Α-ethinyl-13-β-ethyl-17-β-hydroxy-4-estren-3-one
17-Α-ethynyl-13-ethyl-19-nortestosterone
17Α-ethynyl-13β-ethyl-3-oxo-4-estren-17β-ol
17Α-ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17Α-ethynyl-18-homo-19-nortestosterone
18-Methyl-17-a-ethynyl-19-nortestosterone
18-Methyl-17-alpha-ethynyl-19-nortestosterone
18-Methyl-17-α-ethynyl-19-nortestosterone
18-Methylnorethisterone
Alcala brand OF levonorgestrel
ATHENTIA NEXT
Aventis pharma brand OF levonorgestrel
BAY86-5028
Berlex brand OF levonorgestrel
Capronor
Cerazet
D Norgestrel
D(-)-Norgestrel
D-Norgestrel
Duofem
EMERRES
EMERRES UNA
EZINELLE
FALLBACK SOLO
HER STYLE
Hexal brand OF levonorgestrel
HRA brand 1 OF levonorgestrel
HRA brand 2 OF levonorgestrel
|
ISTERANDA
Jadelle
JAYDESS
KYLEENA
L Norgestrel
Levonelle
LEVONELLE ONE STEP
LEVONELLE-2
Levonorgestrel
LÉVONORGESTREL
Lèvonorgestrel
Levonorgestrel alcala brand
Levonorgestrel berlex brand
Levonorgestrel hexal brand
Levonorgestrel paladin brand
Levonorgestrel wyeth brand
Levonorgestrelum
Levonova
LEVOSERT
LILETTA
L-Norgestrel
l-norgestrel|Norplant®
Microlut
Microluton
Microval
Mirena
Norgeston
NORGESTREL (-)-FORM
NorLevo
Norplant
Norplant 2
NORPLANT II
NORPLANT SYSTEM
Norplant2
Norplant-2
OPCICON ONE-STEP
Ovrette
Paladin brand OF levonorgestrel
Plan b
PLAN B ONE-STEP
Postinor
POSTINOR-2
Schering brand 1 OF levonorgestrel
Schering brand 2 OF levonorgestrel
Schering brand 3 OF levonorgestrel
SKYLA
UPOSTELLE
Vikela
Women's capital brand OF levonorgestrel
WY-3707
WY-5104
Wyeth brand OF levonorgestrel
|
|
45 |
|
Olaparib |
Approved |
Phase 1, Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
46 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
47 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 2 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
48 |
|
Megestrol acetate |
Approved, Investigational, Vet_approved |
Phase 2 |
|
595-33-5 |
11683 |
Synonyms:
17-ACETOXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE
17ALPHA-ACETOXY-6-DEHYDRO-6-METHYLPROGESTERONE
17ALPHA-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE ACETATE
17-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE 17-ACETATE
17Α-ACETOXY-6-DEHYDRO-6-METHYLPROGESTERONE
17Α-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE ACETATE
5071
6-DEHYDRO-6-METHYL-17ALPHA-ACETOXYPROGESTERONE
6-DEHYDRO-6-METHYL-17Α-ACETOXYPROGESTERONE
6-METHYL-17ALPHA-ACETOXYPREGNA-4,6-DIENE-3,20-DIONE
6-METHYL-17ALPHA-HYDROXY-DELTA(SUP 6)-PROGESTERONE ACETATE
6-METHYL-17Α-ACETOXYPREGNA-4,6-DIENE-3,20-DIONE
6-METHYL-17Α-HYDROXY-DELTA(SUP 6)-PROGESTERONE ACETATE
6-METHYL-6-DEHYDRO-17ALPHA-ACETOXYPROGESTERONE
6-METHYL-6-DEHYDRO-17Α-ACETOXYPROGESTERONE
6-METHYL-DELTA(SUP 4,6)-PREGNADIEN-17ALPHA-OL-3,20-DIONE ACETATE
6-METHYL-DELTA(SUP 4,6)-PREGNADIEN-17Α-OL-3,20-DIONE ACETATE
6-METHYL-DELTA(SUP 6)-DEHYDRO-17ALPHA-ACETOXYPROGESTERONE
6-METHYL-DELTA(SUP 6)-DEHYDRO-17Α-ACETOXYPROGESTERONE
|
BDH-1298
MAGESTIN
MAYGACE
MEGACE
MEGACE ES
MEGERON
MEGESTAT
MEGESTIL
MEGESTIN
MEGESTROL
MEGESTROL ACETATE
MGA
NIA
NIAGESTIN
NSC-71423
OVABAN
OVARID
SC-10363
VOLIDAN
|
|
49 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
50 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
Interventional clinical trials:
(show top 50)
(show all 80)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma |
Unknown status |
NCT00807768 |
Phase 3 |
Carboplatin;Paclitaxel |
2 |
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer |
Completed |
NCT00063999 |
Phase 3 |
Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel |
3 |
A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III |
Completed |
NCT00002706 |
Phase 3 |
|
4 |
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma |
Completed |
NCT00006011 |
Phase 3 |
Doxorubicin Hydrochloride;Cisplatin;Paclitaxel |
5 |
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer |
Active, not recruiting |
NCT02065687 |
Phase 2, Phase 3 |
Carboplatin;Metformin Hydrochloride;Paclitaxel |
6 |
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma |
Active, not recruiting |
NCT00942357 |
Phase 3 |
Carboplatin;Cisplatin;Paclitaxel |
7 |
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer |
Active, not recruiting |
NCT04214067 |
Phase 3 |
|
8 |
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer |
Active, not recruiting |
NCT03914612 |
Phase 3 |
Carboplatin;Paclitaxel |
9 |
Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) |
Active, not recruiting |
NCT03422198 |
Phase 3 |
|
10 |
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel |
Active, not recruiting |
NCT02501954 |
Phase 3 |
Cisplatin;Carboplatin;Paclitaxel |
11 |
A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy |
Terminated |
NCT00577317 |
Phase 3 |
|
12 |
Phase II Study of Faslodex ? in Recurrent/Metastatic Endometrial Carcinoma |
Unknown status |
NCT00006903 |
Phase 2 |
Fulvestrant |
13 |
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer |
Completed |
NCT01005329 |
Phase 2 |
Carboplatin;Cisplatin;Paclitaxel |
14 |
A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma |
Completed |
NCT00729586 |
Phase 2 |
Megestrol Acetate;Tamoxifen Citrate;Temsirolimus |
15 |
A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer |
Completed |
NCT01010126 |
Phase 2 |
Temsirolimus |
16 |
A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus |
Completed |
NCT00064025 |
Phase 2 |
Medroxyprogesterone |
17 |
A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma |
Completed |
NCT00478426 |
Phase 2 |
Sunitinib Malate |
18 |
A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy |
Completed |
NCT00006089 |
Phase 2 |
|
19 |
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations |
Completed |
NCT02728258 |
Phase 2 |
Copanlisib |
20 |
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer |
Completed |
NCT03180294 |
Phase 2 |
Bupropion 150 mg XL;Placebo |
21 |
A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma |
Recruiting |
NCT03008408 |
Phase 2 |
Everolimus;Letrozole;Ribociclib |
22 |
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer |
Recruiting |
NCT03660826 |
Phase 2 |
Capivasertib;Cediranib;Cediranib Maleate;Olaparib |
23 |
Molecular Analysis for Therapy Choice (MATCH) |
Recruiting |
NCT02465060 |
Phase 2 |
Adavosertib;Afatinib;Afatinib Dimaleate;Binimetinib;Capivasertib;Copanlisib;Copanlisib Hydrochloride;Crizotinib;Dabrafenib;Dabrafenib Mesylate;Dasatinib;Defactinib;Defactinib Hydrochloride;Erdafitinib;FGFR Inhibitor AZD4547;Ipatasertib;Larotrectinib;Larotrectinib Sulfate;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Ulixertinib;Vismodegib |
24 |
A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer |
Active, not recruiting |
NCT02684227 |
Phase 2 |
Carboplatin;Enzalutamide;Paclitaxel |
25 |
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer |
Active, not recruiting |
NCT00977574 |
Phase 2 |
Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus |
26 |
Step Into Wellness: A Program of Health and Recovery for Endometrial Cancer Survivors |
Active, not recruiting |
NCT03367923 |
Phase 2 |
|
27 |
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer |
Active, not recruiting |
NCT01935934 |
Phase 2 |
Cabozantinib S-malate |
28 |
A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma |
Active, not recruiting |
NCT00788671 |
Phase 2 |
|
29 |
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer |
Active, not recruiting |
NCT03367741 |
Phase 2 |
Cabozantinib S-malate |
30 |
A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Active, not recruiting |
NCT02208375 |
Phase 1, Phase 2 |
Capivasertib;Olaparib;Vistusertib |
31 |
A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma |
Active, not recruiting |
NCT03348631 |
Phase 2 |
Tazemetostat |
32 |
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression |
Active, not recruiting |
NCT02059265 |
Phase 2 |
Dasatinib |
33 |
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus |
Active, not recruiting |
NCT00492778 |
Phase 2 |
Cisplatin |
34 |
A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer |
Active, not recruiting |
NCT02874430 |
Phase 2 |
Metformin Hydrochloride;Doxycycline |
35 |
A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer |
Not yet recruiting |
NCT05538897 |
Phase 1, Phase 2 |
Ipatasertib;Megestrol Acetate |
36 |
A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging |
Terminated |
NCT01041027 |
Phase 2 |
Paclitaxel;Carboplatin |
37 |
A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma |
Terminated |
NCT02112552 |
Phase 2 |
Paclitaxel;Carboplatin |
38 |
A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation |
Terminated |
NCT00503581 |
Phase 2 |
Megestrol Acetate |
39 |
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors |
Completed |
NCT01522820 |
Phase 1 |
Sirolimus |
40 |
Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer |
Completed |
NCT01440998 |
Phase 1 |
Carboplatin;Dasatinib;Paclitaxel |
41 |
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure |
Completed |
NCT00575952 |
Phase 1 |
Cisplatin;Doxorubicin Hydrochloride;Paclitaxel |
42 |
A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors |
Completed |
NCT00410553 |
Phase 1 |
Eribulin Mesylate;Gemcitabine Hydrochloride |
43 |
Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy |
Completed |
NCT00005840 |
Phase 1 |
Paclitaxel;Cisplatin |
44 |
Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma |
Completed |
NCT00005830 |
Phase 1 |
Doxorubicin Hydrochloride;Cisplatin |
45 |
A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973 |
Completed |
NCT01935973 |
Phase 1 |
Trametinib;Uprosertib |
46 |
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial) |
Recruiting |
NCT04704661 |
Phase 1 |
Ceralasertib |
47 |
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA) |
Recruiting |
NCT05269381 |
Phase 1 |
Cyclophosphamide |
48 |
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax |
Recruiting |
NCT05092373 |
Phase 1 |
Cabozantinib S-malate;Nab-paclitaxel |
49 |
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors |
Recruiting |
NCT05039801 |
Phase 1 |
Glutaminase Inhibitor IPN60090;Bevacizumab;Paclitaxel |
50 |
Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) |
Recruiting |
NCT04329494 |
Phase 1 |
Cisplatin;Doxorubicin;Fluorouracil;Irinotecan;Leucovorin;Mitomycin;Oxaliplatin |
|